Donald A. Wuchterl, Director at Abeona Therapeutics Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Donald A. Wuchterl became an Abeona director on April 14, 2021 and serves on the Nominating and Corporate Governance Committee and the Audit Committee. Since August 2022 he has provided Chemistry, Manufacturing and Controls (CMC) and Technical Operations executive-leadership consulting to pre-clinical gene therapy companies. From April 2021 to August 2022 he was Senior Vice President and Chief Manufacturing Officer at T-knife Therapeutics, and from 2016 to 2021 he was Senior Vice President, Technical Operations and Quality at Audentes Therapeutics (an Astellas company). From 2012 to 2016 he was Senior Vice President and Chief Operating Officer at Cytovance Biologics, and earlier held roles at Dendreon, Shire HGT, Amgen, Biogen Idec and Roche. He holds a B.S. in Business Administration from Colorado Technical University and an MBA from Fitchburg State University.
Roles
Abeona Therapeutics Inc.
Director · Current role
April 2021–present
Independent consultant (CMC and Technical Operations)
Executive-leadership consulting to pre-clinical gene therapy companies
ComponentAnnual board fee plus committee and committee-chair fees earned in 2025, paid quarterly
Stock awards
$200,000
ComponentRestricted stock award for 2025 Board service (36,101 shares granted January 31, 2025 at $5.54, ASC 718 grant-date fair value); vests one year after grant